Oncotarget

Research Papers:

A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme

Hayley Nehoff _, Neha N. Parayath, Melanie J. McConnell, Sebastien Taurin and Khaled Greish

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:37948-37964. https://doi.org/10.18632/oncotarget.5698

Metrics: PDF 1094 views  |   HTML 2151 views  |   ?  


Abstract

Hayley Nehoff1, Neha N. Parayath1, Melanie J. McConnell2, Sebastien Taurin1, Khaled Greish1

1Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand

2School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand

Correspondence to:

Sebastien Taurin, e-mail: sebastien.taurin@otago.ac.nz

Keywords: glioblastoma multiforme, tyrosine kinase inhibitors, invasion, Met, SRC

Received: April 23, 2015     Accepted: October 06, 2015     Published: October 16, 2015

ABSTRACT

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor. Despite the advances in surgery, radiotherapy and chemotherapy, patient survival averages only 14.6 months. In most GBM tumors, tyrosine kinases show increased activity and/or expression and actively contribute to the development, recurrence and onset of treatment resistance; making their inhibition an appealing therapeutic strategy. We compared the cytotoxicity of 12 tyrosine kinase inhibitors in vitro. A combination of crizotinib and dasatinib emerged as the most cytotoxic across established and primary human GBM cell lines. The combination treatment induced apoptotic cell death and polyploidy. Furthermore, the combination treatment led to the altered expression and localization of several tyrosine kinase receptors such as Met and EGFR and downstream effectors as such as SRC. Furthermore, the combination treatment reduced the migration and invasion of GBM cells and prevented endothelial cell tube formation in vitro. Overall, our study demonstrated the broad specificity of a combination of crizotinib and dasatinib across multiple GBM cell lines. These findings provide insight into the development of alternative therapy for the treatment of GBM.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5698